Business
PRTC'S Vedanta Expands Leadership Team
PRTC'S Vedanta Expands Leadership Team.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n23 July 2024\nPureTech Health plc\n \nPureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial\nAppointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity\nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vedanta Biosciences, a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases, today announced three appointments to its leadership team. Christof Marré, a seasoned biopharma marketing leader, joins the company as Senior Vice President and Head of Commercial. In addition, Steven Shiff, M.D., a pharmaceutical executive and physician specializing in gastroenterology, has been appointed as SVP, Clinical Research; and Jack Kyte has been promoted to SVP, Human Resources.\n \nThe full text of the announcement from Vedanta is as follows:\n \nVedanta Biosciences Expands Leadership Team and Appoints Head of Commercial\nAppointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity\nCAMBRIDGE, MA, July 23, 2024 - Vedanta Biosciences, a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases, today announced three appointments to its leadership team. Christof Marré, a seasoned biopharma marketing leader, joins the company as Senior Vice President and Head of Commercial. In addition, Steven Shiff, M.D., a pharmaceutical executive and physician specializing in gastroenterology, has been appointed as SVP, Clinical Research; and Jack Kyte has been promoted to SVP, Human Resources.\n \n\"I am delighted to welcome Christof and Steve to the team,\" said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. \"The expertise that Christof, Steve, and Jack bring are vital to our next phase of growth as we execute our ongoing pivotal Phase 3 RESTORATiVE303 trial of VE303 for C. difficile infection and Phase 2 COLLECTiVE202 trial of VE202 for ulcerative colitis, and establis...